Literature DB >> 7587161

MARKOV: a computer program for multi-state Markov models with covariables.

G Marshall1, W Guo, R H Jones.   

Abstract

This paper discusses a computer program, called MARKOV, designed to fit a multi-state Markov model with covariables, with a particular emphasis on the analysis of survival data. The Markov model consists of k-1 transient disease states and one absorbing state. The exact transition times are not observed, except in situations such as death. Baseline transition intensities and regression coefficients are estimated via the method of maximum likelihood using a quasi-Newton optimization algorithm. The program's output includes the parameter estimates, the standard error of the estimates, the matrix of the correlation of the estimates and minus two times the log-likelihood function, evaluated at the initial values and at the maximum likelihood estimates. Optionally, survival curves can be generated from each transient state, for one or more combination of covariable values and simple tests about the parameters. The program is illustrated by using a four-state model to determine factors influencing diabetic retinopathy in young subjects with insulin-dependent diabetes mellitus.

Entities:  

Mesh:

Year:  1995        PMID: 7587161     DOI: 10.1016/0169-2607(95)01641-6

Source DB:  PubMed          Journal:  Comput Methods Programs Biomed        ISSN: 0169-2607            Impact factor:   5.428


  4 in total

1.  Multi-state models in epidemiology.

Authors:  D Commenges
Journal:  Lifetime Data Anal       Date:  1999-12       Impact factor: 1.588

2.  A population-based assessment of the prognostic value of the CD19 positive lymphocyte count in B-cell chronic lymphocytic leukemia using Cox and Markov models.

Authors:  R Cailliod; C Quantin; P M Carli; V Jooste; G Le Teuff; C Binquet; M Maynadie
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

3.  Multi-state models for the analysis of time-to-event data.

Authors:  Luís Meira-Machado; Jacobo de Uña-Alvarez; Carmen Cadarso-Suárez; Per K Andersen
Journal:  Stat Methods Med Res       Date:  2008-06-18       Impact factor: 3.021

4.  Cost-Effectiveness of Three Alternative Boosted Protease Inhibitor-Based Second-Line Regimens in HIV-Infected Patients in West and Central Africa.

Authors:  S Boyer; M L Nishimwe; L Sagaon-Teyssier; L March; S Koulla-Shiro; M-Q Bousmah; R Toby; M P Mpoudi-Etame; N F Ngom Gueye; A Sawadogo; C Kouanfack; L Ciaffi; B Spire; E Delaporte
Journal:  Pharmacoecon Open       Date:  2020-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.